Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine + Docetaxel in mCRPC
NCT00503984Phase 2Terminated
- Sponsor
- University of Miami
- Start
- May 2007
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Miami. Started May 2007; status: terminated.
02
Drugs
azacitidine
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00503984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00503984.